Human clinical trials are limited, and optimal dosing, long-term safety, and comparative effectiveness with other therapies remain unclear
Studies have shown that SGLT-2 inhibitors can induce weight loss of 2%-3% and may lead to improvement of hepatic steatosis and fibrosis [139,140]
The agency periodically updates prescribing information and issues safety communications when new evidence warrants changes to clinical practice recommendations
Bauer M, London ED, Silverman DH, et al
In A142induced rodent models of Alzheimers disease, astaxanthin treatmentadministered in different formulations, consistently improved cognitive performance and reduced oxidative stress, neuroinflammation, and histopathological hallmarks compared with untreated or vehicle-treated controls